PTEN and breast carcinoma: Introduction of phosphatase-deficient forms of PTEN or kinase-dead GSK-3beta will also alter the sensitivity of breast cancer cells to chemotherapeutic drugs and in some cases hormonal based therapies such as tamoxifen and targeted therapies such as rapamycin [5, 6, 10].